Therapy Areas: Oncology
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
29 January 2026 - Biopharmaceutical oncology company Summit Therapeutics Inc (NASDAQ:SMMT) announced on Thursday that the US Food and Drug Administration (FDA) has accepted its Biologics License Appli...
InSysBio agrees new collaborative project with BeOne Medicines
29 January 2026 - Quantitative Systems Pharmacology (QSP) modelling specialist InSysBio announced on Wednesday an extension of its collaboration with oncology company BeOne Medicines.In this project, ...
Physiomics secures new modelling contract with Numab Therapeutics
28 January 2026 - Mathematical modelling, data science and biostatistics company Physiomics plc (AIM: PYC) announced on Wednesday that it has been awarded a new contract by long-standing client Numab ...
HanchorBio partners with WuXi Biologics for development and manufacturing of next-gen bi- and multi-functional fusion programmes
27 January 2026 - HanchorBio Inc (TPEx:7827), a clinical-stage biotechnology company advancing next-generation immunotherapies for oncology and autoimmune diseases, announced on Monday that it has ent...
MS Pharma enters strategic partnership with Hetero Group
27 January 2026 - MS Pharma Group, a Jordan-based pharmaceutical company, announced on Monday that it has entered into a strategic partnership with Hetero Group, a manufacturer of Active Pharmaceutica...
PhotonPharma adds Dr. William Warren to board
23 January 2026 - PhotonPharma Inc, a developer of autologous cancer immunotherapies, announced on Thursday the appointment of William Warren, Ph.D. to its board of directors.PhotonPharma says that Dr...